Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 1, 2000, Pages 57-62

  Dowzicky, M ^a   Talbot, G H ^a   Feger, C ^a   Prokocimer, P ^a   Etienne, J ^b   Leclercq, R ^c  

^a SANOFI   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; MAJOR CLINICAL STUDY; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; HUMANS; INTERNATIONAL COOPERATION; PNEUMONIA, BACTERIAL; PNEUMONIA, STAPHYLOCOCCAL; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRGINIAMYCIN; WORLD HEALTH;

EID: 0034049349     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00154-6     Document Type: Article

References (28)

1. Baughman R for the US Synercid® CAP Study Group (1997). Randomized, comparative, multicenter study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus combination of ceftriaxone and erythromycin in the treatment of acute community-acquired bacterial pneumonia (CAP). In Abstracts of the 20th International Congress of Chemotherapy. Sydney, Australia. International Society of Chemotherapy.
2. Beal J for the Global Synercid® SSSI Study Group (1997). Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Abstracts of the 20th International Congress of Chemotherapy. Sydney, Australia. International Society of Chemotherapy.
3. Bouanchaud, D. H. (1992). In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 30, (suppl A), 95-99.
4. Bozdogan, B. & Leclercq, R. (1997). Intrinsic and acquired resistance to dalfopristin (streptogramin A) in Enterococcus spp. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington D.C.
5. Bryson, H. M. & Spencer, C. M. ( 1996). Quinupristin-dalfopristin. Drugs 52, 406-415.
6. Chow J.W., Donabedian S.M., Zervos M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis. 24:1997;90-91.
7. Dutka-Malen, S., Berthaud, N., & Desnottes, J-F. (1996). RP 57669/RP 54476 (RP 59500): Resistance mutation frequencies in Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Haemophilus influenzae and Streptococcus pneumoniae. RPR/RD/DISC/BIOL/CRVA 859. 10 Nov 96. Data on file.
8. El Solh, N., Loncle, V., Aubert, S., Casetta, A., & Allignet, J. (1993). Analysis of staphylococcal elements conferring resistance to streptogramin A(RP 54476), 217, p, 159:In Abstracts of the33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
9. Fagon, J-Y., Patrick, H., Haas, D. W., Torres, A., Gibert, C., Cheadle, W. G., Falcone, R. E., Anholm, J. D., Paganin, F., Fabian, T. C., Lilienthal, F., & the Nosocomial Pneumonia Group (1999). Treatment of Gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Resp Crit Care Med in press.
10. Fantin B., Leclercq R., Garry L., Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother. 41:1997;931-935.
11. Fish D.N., Piscitelli S.C., Danziger L.H. Development of resistance during antimicrobial therapy A review of antibiotic classes and patient characteristics in 173 studies . Pharmacotherapy. 15:1995;279-291.
12. Gazagne, L., Geudet, P., Lecaillon, E., Le Coustumier, A., Bismuth, R., & 'Le Collège de Bactériologie, Virologie et Hygiène des Hôpitaux de France' (1998). In vitro activity of streptogramins against 45 methicillin-resistant Staphylococcus aureus with decreased susceptibility to dalfopristin. In Abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. American Society for Microbiology, Washington, DC.
13. Goering R.V., Winters M.A. Rapid method for epidemiological evaluation of Gram-positive cocci by field inversion gel electrophoresis. J Clin Microbiol. 30:1992;577-580.
14. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin-dalfopristin (RP59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centres in the United States and Canada. Diagn Microbiol Infect Dis. 31:1998;437-451.
15. Leclercq R., Nantas L., Soussy C.J., Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 30:(suppl A):1992;67-75.
16. Lina B., Vandenesch F., Etienne J., Kreiswirth B., Fleurette J. Comparison of coagulase-negative staphylococci by pulsed-field gel electrophoresis. FEMS Microbiol Lett. 92:1992;133-138.
17. Lina G., Quaglia A., Reverdy M.E., Leclercq R., Vandenesch F., Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother. 43:1999;1062-1066.
18. Millichap J., Ristow T.A., Noskin G.A., Peterson L.R. Selection of Enterococcus faecium strains with stable and unstable resistance to the streptogramin RP 59500 using stepwise in vitro exposure. Diagn Microbiol Infect Dis. 25:1996;15-20.
19. Moellering, R. C., Linden, P. K., Reinhardt, J., Blumberg, E. A., Bompart, F., Talbot, G. H., for the Synercid Emergency-Use Study Group (1999). The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 44, 251-261.
20. Mulazimoglu, L., Drenning, S. D., & Yu, V. L. (1996). In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 40, 2428-2430.
21. Murray B.E., Singh K., Health J.D., Sharma B.R., Weinstock G.M. Comparison of genomic DNAs of different enterococcal isolates using restriction endonucleases with infrequent recognition sites. J Clin Microbiol. 28:1990;2059-2063.
22. National Committee for Clinical Laboratory Standards (1993). Methods for dilution antimicrobial susceptibility tests for bacteria grown aerobically. Approved standard M7-A3 (3rd edition). National Committee for Clinical Laboratory Standards, Villanova, PA, USA.
23. National Committee for Clinical Laboratory Standards (1998). Subcommittee on Antimicrobial Susceptibility Testing, Minutes of June1998 meeting. Reston, VA, USA.
24. Nichols, R. L., Graham, D. R., Barriere, S. L., Rodgers, A., Wilson, S. E., Zervos, M., Dunn, D. L., Kreter, B., for the Synercid Skin and Skin Structure Infection Group (1999). Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 44, 263-273.
25. Sutcliffe J., Grebe T., Tait-Kamradt A., Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother. 40:1996;2562-2566.
26. Thabaut, A., Etienne, J., Leclercq, R., Dabernat, H., Dubreuil, L., Geslin, P., Feger, C., & Scheimberg, A. (1999). Update on the in vitro activity of quinupristin/dalfopristin against bacterial isolates from hospitals in France. Data on file.
27. Vannuffel P., Cocito C. Mechanism of action of streptogramins and macrolides. Drugs. 50:(suppl 1):1996;20-30.
28. Wood, C. A., Blumberg, E. A., Fuchs, A. E., Molavi, A., Mandler, H. D., Smith-Davis, J., & Hartstein, A.I. (1998). Emergence of resistance to quinupristin/dalfopristin (Synercid) during treatment of infections caused by vancomycin-resistant Enterococcus faecium. Program and Abstracts of the Infectious Diseases Society of America, 36th Annual Meeting:Denver, Colorado, November12-15, 1998, p 190 (abstract no 607 Fr).